Additional file 1 of Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Clatot, Florian; Perdrix, Anne; Beaussire, Ludivine; Lequesne, Justine; Lévy, Christelle; Emile, George; Bubenheim, Michael; Lacaille, Sigrid; Calbrix, Céline; Augusto, Laetitia; Guillemet, Cécile; Alexandru, Cristina; Fontanilles, Maxime; Sefrioui, David; Burel, Lucie; Guénot, Sabine; Richard, Doriane; Sarafan-Vasseur, Nasrin; Di Fiore, Frédéric

doi:10.6084/m9.figshare.12386327.v1

13058_2020_1290_MOESM1_ESM.docx (144.72 kB)

Additional file 1 of Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

journal contribution

posted on 2020-05-29, 03:39 authored by Florian Clatot, Anne Perdrix, Ludivine Beaussire, Justine Lequesne, Christelle Lévy, George Emile, Michael Bubenheim, Sigrid Lacaille, Céline Calbrix, Laetitia Augusto, Cécile Guillemet, Cristina Alexandru, Maxime Fontanilles, David Sefrioui, Lucie Burel, Sabine Guénot, Doriane Richard, Nasrin Sarafan-Vasseur, Frédéric Di Fiore

Additional file 1. Provides the following survival curves: PFS according to cfDNA level at baseline. OS according to cfDNA level at baseline. PFS according to CA-15.3 level at baseline. OS according to CA-15.3 level at baseline.

Funding

AstraZeneca France La ligue contre le cancer de Haute Normandie

History

Usage metrics

Keywords

ESR1 mutation Breast cancer Circulating DNA CA-15.3 Cell-free DNA Aromatase inhibitor

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Funding

AstraZeneca France La ligue contre le cancer de Haute Normandie

History

Usage metrics

Categories

Keywords

Licence

Exports